{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:47:38Z","timestamp":1791852458811,"version":"4.3.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discover Nano"],"DOI":"10.1186\/s11671-026-04973-0","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:06:32Z","timestamp":1791824792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cross database bibliometric and knowledge mapping analysis of nanoplatform mediated tumor associated macrophage reprogramming"],"prefix":"10.1186","volume":"21","author":[{"given":"Chang","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehao","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy Yue","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Aldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Whitmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"5","key":"4973_CR1","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.3390\/ijms27052253","volume":"27","author":"J Puiggal\u00ed","year":"2026","unstructured":"Puiggal\u00ed J. From Nanoparticle Design to Clinical Translation in Cancer Therapy. Int J Mol Sci. 2026;27(5):2253. https:\/\/doi.org\/10.3390\/ijms27052253.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4973_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12943-025-02563-9","volume":"25","author":"A Tiwari","year":"2026","unstructured":"Tiwari A, Widodo, Krisnawati DI, Chen CY, Kuo TR. AI-driven nanomedicine for cancer theranostics. Mol Cancer. 2026;25(1):78. https:\/\/doi.org\/10.1186\/s12943-025-02563-9.","journal-title":"Mol Cancer"},{"key":"4973_CR3","doi-asserted-by":"publisher","first-page":"100372","DOI":"10.1016\/j.nxnano.2026.100372","volume":"9","author":"H Firouzpour","year":"2026","unstructured":"Firouzpour H, Najafi F, Mohammadgholi A, Alizadegan D, Mahmoudi Beram F, Akhtari N, Zoghi M, Ansar N, Yaraki T, M. Nanoparticle-based drug delivery systems for effective cancer treatment: Mechanisms and applications. Next Nanatechnol. 2026;9:100372. https:\/\/doi.org\/10.1016\/j.nxnano.2026.100372.","journal-title":"Next Nanatechnol"},{"issue":"1","key":"4973_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41467-024-55658-0","volume":"16","author":"J Zou","year":"2025","unstructured":"Zou J, Jiang C, Hu Q, Jia X, Wang S, Wan S, Mao Y, Zhang D, Zhang P, Dai B, Li Y. Tumor microenvironment-responsive engineered hybrid nanomedicine for photodynamic-immunotherapy via multi-pronged amplification of reactive oxygen species. Nat Commun. 2025;16(1):424. https:\/\/doi.org\/10.1038\/s41467-024-55658-0.","journal-title":"Nat Commun"},{"issue":"1","key":"4973_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","volume":"10","author":"J Xu","year":"2025","unstructured":"Xu J, Ding L, Mei J, Hu Y, Kong X, Dai S, Bu T, Xiao Q, Ding K. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target therapy. 2025;10(1):268. https:\/\/doi.org\/10.1038\/s41392-025-02325-5.","journal-title":"Signal Transduct Target therapy"},{"issue":"1","key":"4973_CR6","doi-asserted-by":"publisher","first-page":"10395","DOI":"10.1038\/s41467-024-53906-x","volume":"15","author":"J Song","year":"2024","unstructured":"Song J, Wang H, Meng X, Li W, Qi J. A hypoxia-activated and microenvironment-remodeling nanoplatform for multifunctional imaging and potentiated immunotherapy of cancer. Nat Commun. 2024;15(1):10395. https:\/\/doi.org\/10.1038\/s41467-024-53906-x.","journal-title":"Nat Commun"},{"issue":"1","key":"4973_CR7","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1038\/s41467-023-40996-2","volume":"14","author":"X Kang","year":"2023","unstructured":"Kang X, Zhang Y, Song J, Wang L, Li W, Qi J, Tang BZ. A photo-triggered self-accelerated nanoplatform for multifunctional image-guided combination cancer immunotherapy. Nat Commun. 2023;14(1):5216. https:\/\/doi.org\/10.1038\/s41467-023-40996-2.","journal-title":"Nat Commun"},{"issue":"1","key":"4973_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, Lin L. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ precision Oncol. 2024;8(1):31. https:\/\/doi.org\/10.1038\/s41698-024-00522-z.","journal-title":"NPJ precision Oncol"},{"issue":"1","key":"4973_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12943-024-02064-1","volume":"23","author":"X Chu","year":"2024","unstructured":"Chu X, Tian Y, Lv C. Decoding the spatiotemporal heterogeneity of tumor-associated macrophages. Mol Cancer. 2024;23(1):150. https:\/\/doi.org\/10.1186\/s12943-024-02064-1.","journal-title":"Mol Cancer"},{"issue":"9","key":"4973_CR10","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1016\/j.apsb.2025.07.021","volume":"15","author":"AQ Li","year":"2025","unstructured":"Li AQ, Huang F, Talaiti S, Yang X, Bi H, Fang JH. Understanding the complexity of tumor-associated macrophages: Druggable and therapeutic insights. Acta Pharm Sinica B. 2025;15(9):4456\u201375. https:\/\/doi.org\/10.1016\/j.apsb.2025.07.021.","journal-title":"Acta Pharm Sinica B"},{"issue":"3","key":"4973_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/nano16030172","volume":"16","author":"AM Thamizhchelvan","year":"2026","unstructured":"Thamizhchelvan AM, Wells K, Pham J, Galhena A, Kim W. Nanomaterial-Enabled Modulation of Tumor-Associated Macrophages and Dendritic Cells to Enhance Cancer Immunotherapy. Nanomaterials (Basel Switzerland). 2026;16(3):172. https:\/\/doi.org\/10.3390\/nano16030172.","journal-title":"Nanomaterials (Basel Switzerland)"},{"issue":"1","key":"4973_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17425247.2016.1205583","volume":"14","author":"B Xiao","year":"2017","unstructured":"Xiao B, Ma L, Merlin D. Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy. Expert Opin Drug Deliv. 2017;14(1):65\u201373. https:\/\/doi.org\/10.1080\/17425247.2016.1205583.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"4973_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12951-025-03921-x","volume":"24","author":"Y Hou","year":"2025","unstructured":"Hou Y, Wu R, Zhou Y, Yin C, Gai Y, Jiang D, Wang K, Xia X. Macrophage membrane-coated nanoparticles in inflammatory diseases: from bioinspired design to translational potential. J Nanobiotechnol. 2025;24(1):37. https:\/\/doi.org\/10.1186\/s12951-025-03921-x.","journal-title":"J Nanobiotechnol"},{"key":"4973_CR14","doi-asserted-by":"publisher","first-page":"123915","DOI":"10.1016\/j.biomaterials.2025.123915","volume":"329","author":"J Wang","year":"2026","unstructured":"Wang J, Su Z, Zhang X, Wang S, Chen X, Xu X, He B, Zheng Y. Stimuli-responsive nanomaterials for eradicating intratumoral bacteria and augmenting tumor therapy efficiency: progress and perspectives. Biomaterials. 2026;329:123915. https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123915.","journal-title":"Biomaterials"},{"key":"4973_CR15","doi-asserted-by":"publisher","first-page":"1248421","DOI":"10.3389\/fbioe.2023.1248421","volume":"11","author":"J Zheng","year":"2023","unstructured":"Zheng J, Jiang J, Pu Y, Xu T, Sun J, Zhang Q, He L, Liang X. Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms. Front Bioeng Biotechnol. 2023;11:1248421. https:\/\/doi.org\/10.3389\/fbioe.2023.1248421.","journal-title":"Front Bioeng Biotechnol"},{"issue":"13","key":"4973_CR16","doi-asserted-by":"publisher","first-page":"e19127","DOI":"10.1002\/advs.202519127","volume":"13","author":"D Liu","year":"2026","unstructured":"Liu D, Yu J, Li J, Chen Y, Peng M, Xu Y, Wu Y, Ding L, He S. Biomimetic Membrane Interface Technologies for Detection and Isolation of CTCs and EVs: Advances and Opportunities in Liquid Biopsy. Adv Sci (Weinheim Baden-Wurttemberg Germany). 2026;13(13):e19127. https:\/\/doi.org\/10.1002\/advs.202519127.","journal-title":"Adv Sci (Weinheim Baden-Wurttemberg Germany)"},{"issue":"5","key":"4973_CR17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/idm2.12199","volume":"3","author":"Z Ren","year":"2024","unstructured":"Ren Z, Wan Q, Zhu Y, Li L, Wang K, Zhao F, Jiao K, Tang M, Tay F, Wan M, Niu L. Atypical artificial cells: Novel biomimetic materials for combating cancer. Interdisciplinary Mater. 2024;3(5):658\u2013714. https:\/\/doi.org\/10.1002\/idm2.12199.","journal-title":"Interdisciplinary Mater"},{"key":"4973_CR18","doi-asserted-by":"publisher","first-page":"772522","DOI":"10.3389\/fbioe.2021.772522","volume":"9","author":"M Guo","year":"2021","unstructured":"Guo M, Xia C, Wu Y, Zhou N, Chen Z, Li W. Research Progress on Cell Membrane-Coated Biomimetic Delivery Systems. Front Bioeng Biotechnol. 2021;9:772522. https:\/\/doi.org\/10.3389\/fbioe.2021.772522.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"4973_CR19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s12672-025-02473-8","volume":"16","author":"A Luan","year":"2025","unstructured":"Luan A, Zhang Y, Yang L, Zhao G, Yang X. Global research trends in tumor-associated macrophage studies: a bibliometric analysis. Discover Oncol. 2025;16(1):711. https:\/\/doi.org\/10.1007\/s12672-025-02473-8.","journal-title":"Discover Oncol"},{"issue":"1","key":"4973_CR20","doi-asserted-by":"publisher","first-page":"2512656","DOI":"10.1080\/21645515.2025.2512656","volume":"21","author":"Y Gao","year":"2025","unstructured":"Gao Y, Yuan W, Zhang J, Wang Z, Cui W, Guan Z. A two-decade bibliometric analysis of tumor-associated macrophages in colorectal cancer research. Hum vaccines immunotherapeutics. 2025;21(1):2512656. https:\/\/doi.org\/10.1080\/21645515.2025.2512656.","journal-title":"Hum vaccines immunotherapeutics"},{"issue":"1","key":"4973_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s12672-025-04244-x","volume":"17","author":"C Han","year":"2025","unstructured":"Han C, Huang C, Fang Y. Research trends and emerging frontiers of tumor-associated macrophages in gastric cancer: a bibliometric analysis. Discover Oncol. 2025;17(1):176. https:\/\/doi.org\/10.1007\/s12672-025-04244-x.","journal-title":"Discover Oncol"},{"key":"4973_CR22","doi-asserted-by":"publisher","first-page":"1446532","DOI":"10.3389\/fimmu.2024.1446532","volume":"15","author":"C Chen","year":"2024","unstructured":"Chen C, Yuan P, Zhang Z. Nanomedicine-based cancer immunotherapy: a bibliometric analysis of research progress and prospects. Front Immunol. 2024;15:1446532. https:\/\/doi.org\/10.3389\/fimmu.2024.1446532.","journal-title":"Front Immunol"},{"issue":"6","key":"4973_CR23","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1177\/0193841X251336839","volume":"49","author":"AD Hoang","year":"2025","unstructured":"Hoang AD. Evaluating Bibliometrics Reviews: A Practical Guide for Peer Review and Critical Reading. Eval Rev. 2025;49(6):1074\u2013102. https:\/\/doi.org\/10.1177\/0193841X251336839.","journal-title":"Eval Rev"},{"key":"4973_CR24","doi-asserted-by":"publisher","first-page":"102100","DOI":"10.1016\/j.mtbio.2025.102100","volume":"34","author":"R Zhao","year":"2025","unstructured":"Zhao R, Liang B, Shi Y, Gao J, Wang X, Shao T, Xing K, Yan M, Wang T, Zhang Y, Xing D. Immunomodulatory biomaterials for osteoarthritis: Targeting inflammation and enhancing cartilage regeneration. Mater today Bio. 2025;34:102100. https:\/\/doi.org\/10.1016\/j.mtbio.2025.102100.","journal-title":"Mater today Bio"},{"key":"4973_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.bioactmat.2026.01.040","volume":"60","author":"H Fu","year":"2026","unstructured":"Fu H, Gao W, Tang Y, Liu X, Wang M, Zhang J, Liu T, Zhang J. Programmable next-generation supramolecular self-assembled materials as drug delivery systems. Bioactive Mater. 2026;60:539\u201373. https:\/\/doi.org\/10.1016\/j.bioactmat.2026.01.040.","journal-title":"Bioactive Mater"},{"key":"4973_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bioactmat.2024.04.004","volume":"38","author":"Q Guo","year":"2024","unstructured":"Guo Q, Qian ZM. Macrophage based drug delivery: Key challenges and strategies. Bioactive Mater. 2024;38:55\u201372. https:\/\/doi.org\/10.1016\/j.bioactmat.2024.04.004.","journal-title":"Bioactive Mater"},{"issue":"2","key":"4973_CR27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1515\/jtim-2025-0020","volume":"13","author":"Y Guo","year":"2025","unstructured":"Guo Y, Huang J, Lin M, Yin Q, Zhang T, Guo Z, Tang Y, Cheng R, Wang Y, Peng Y, Cao X, Wang Y, Qi X, Liu Y, Xue L. Nano particle loaded EZH2 inhibitors: Increased efficiency and reduced toxicity for malignant solid tumors. J translational Intern Med. 2025;13(2):156\u201369. https:\/\/doi.org\/10.1515\/jtim-2025-0020.","journal-title":"J translational Intern Med"},{"issue":"1","key":"4973_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jconrel.2012.01.034","volume":"160","author":"A Etzerodt","year":"2012","unstructured":"Etzerodt A, Maniecki MB, Graversen JH, M\u00f8ller HJ, Torchilin VP, Moestrup SK. Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. J controlled release: official J Controlled Release Soc. 2012;160(1):72\u201380. https:\/\/doi.org\/10.1016\/j.jconrel.2012.01.034.","journal-title":"J controlled release: official J Controlled Release Soc"},{"key":"4973_CR29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.biomaterials.2015.07.035","volume":"67","author":"DY Gao","year":"2015","unstructured":"Gao DY, Lin TsT, Sung YC, Liu YC, Chiang WH, Chang CC, Liu JY, Chen Y. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. Biomaterials. 2015;67:194\u2013203. https:\/\/doi.org\/10.1016\/j.biomaterials.2015.07.035.","journal-title":"Biomaterials"},{"key":"4973_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.biomaterials.2016.09.034","volume":"112","author":"Y Wang","year":"2017","unstructured":"Wang Y, Lin YX, Qiao SL, An HW, Ma Y, Qiao ZY, Rajapaksha RP, Wang H. Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. Biomaterials. 2017;112:153\u201363. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.09.034.","journal-title":"Biomaterials"},{"issue":"1","key":"4973_CR31","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1186\/s12951-024-02835-4","volume":"22","author":"H Mengyuan","year":"2024","unstructured":"Mengyuan H, Aixue L, Yongwei G, Qingqing C, Huanhuan C, Xiaoyan L, Jiyong L. Biomimetic nanocarriers in cancer therapy: based on intercellular and cell-tumor microenvironment communication. J Nanobiotechnol. 2024;22(1):604. https:\/\/doi.org\/10.1186\/s12951-024-02835-4.","journal-title":"J Nanobiotechnol"},{"issue":"9","key":"4973_CR32","doi-asserted-by":"publisher","first-page":"8977","DOI":"10.1021\/acsnano.8b02446","volume":"12","author":"YW Choo","year":"2018","unstructured":"Choo YW, Kang M, Kim HY, Han J, Kang S, Lee JR, Jeong GJ, Kwon SP, Song SY, Go S, Jung M, Hong J, Kim BS. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors. ACS Nano. 2018;12(9):8977\u201393. https:\/\/doi.org\/10.1021\/acsnano.8b02446.","journal-title":"ACS Nano"},{"issue":"1","key":"4973_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1021\/acsnano.5b06779","volume":"10","author":"M Song","year":"2016","unstructured":"Song M, Liu T, Shi C, Zhang X, Chen X. Bioconjugated Manganese Dioxide Nanoparticles Enhance Chemotherapy Response by Priming Tumor-Associated Macrophages toward M1-like Phenotype and Attenuating Tumor Hypoxia. ACS Nano. 2016;10(1):633\u201347. https:\/\/doi.org\/10.1021\/acsnano.5b06779.","journal-title":"ACS Nano"},{"key":"4973_CR34","doi-asserted-by":"publisher","first-page":"120456","DOI":"10.1016\/j.biomaterials.2020.120456","volume":"265","author":"Y Yang","year":"2021","unstructured":"Yang Y, Liu X, Ma W, Xu Q, Chen G, Wang Y, Xiao H, Li N, Liang XJ, Yu M, Yu Z. Light-activatable liposomes for repetitive on-demand drug release and immunopotentiation in hypoxic tumor therapy. Biomaterials. 2021;265:120456. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120456.","journal-title":"Biomaterials"},{"key":"4973_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jconrel.2020.02.011","volume":"321","author":"M Li","year":"2020","unstructured":"Li M, Li M, Yang Y, Liu Y, Xie H, Yu Q, Tian L, Tang X, Ren K, Li J, Zhang Z, He Q. Remodeling tumor immune microenvironment via targeted blockade of PI3K-\u03b3 and CSF-1\/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy. J controlled release: official J Controlled Release Soc. 2020;321:23\u201335. https:\/\/doi.org\/10.1016\/j.jconrel.2020.02.011.","journal-title":"J controlled release: official J Controlled Release Soc"},{"key":"4973_CR36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.bioactmat.2023.11.017","volume":"33","author":"X Deng","year":"2023","unstructured":"Deng X, Liu T, Zhu Y, Chen J, Song Z, Shi Z, Chen H. Ca & Mn dual-ion hybrid nanostimulator boosting anti-tumor immunity via ferroptosis and innate immunity awakening. Bioactive Mater. 2023;33:483\u201396. https:\/\/doi.org\/10.1016\/j.bioactmat.2023.11.017.","journal-title":"Bioactive Mater"},{"issue":"7","key":"4973_CR37","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.1021\/acsnano.4c10202","volume":"19","author":"X Lu","year":"2025","unstructured":"Lu X, Xia H, Gao W, Pan X, Yan Y, Zhang R, He Y, Wang Y, Chen B, Mei D. A pH-Responsive and Guanidinium-Rich Nanoadjuvant Efficiently Delivers STING Agonist for Cancer Immunotherapy. ACS Nano. 2025;19(7):6758\u201370. https:\/\/doi.org\/10.1021\/acsnano.4c10202.","journal-title":"ACS Nano"},{"issue":"6","key":"4973_CR38","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1515\/jtim-2025-0093","volume":"13","author":"J Zhou","year":"2025","unstructured":"Zhou J, Yang W, Tang H, Zou Y, Zhou Z, Peng C, Peng F. Co-targeting ferroptosis and immune evasion through small molecules in breast cancer. J translational Intern Med. 2025;13(6):516\u201336. https:\/\/doi.org\/10.1515\/jtim-2025-0093.","journal-title":"J translational Intern Med"},{"issue":"8\u20139","key":"4973_CR39","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.imbio.2017.05.011","volume":"222","author":"PA Alvarado-Vazquez","year":"2017","unstructured":"Alvarado-Vazquez PA, Bernal L, Paige CA, Grosick RL, Vilrriales M, Ferreira C, Ulecia-Mor\u00f3n DW, C., Romero-Sandoval EA. Macrophage-specific nanotechnology-driven CD163 overexpression in human macrophages results in an M2 phenotype under inflammatory conditions. Immunobiology. 2017;222(8\u20139):900\u201312. https:\/\/doi.org\/10.1016\/j.imbio.2017.05.011.","journal-title":"Immunobiology"},{"issue":"15","key":"4973_CR40","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.3390\/ijms21155497","volume":"21","author":"MK Skytthe","year":"2020","unstructured":"Skytthe MK, Graversen JH, Moestrup SK. Targeting of CD163\u2009+\u2009Macrophages in Inflammatory and Malignant Diseases. Int J Mol Sci. 2020;21(15):5497. https:\/\/doi.org\/10.3390\/ijms21155497.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4973_CR41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s40820-021-00622-6","volume":"13","author":"Q Chen","year":"2021","unstructured":"Chen Q, Sun T, Jiang C. Recent Advancements in Nanomedicine for \u2018Cold\u2019 Tumor Immunotherapy. Nano-micro Lett. 2021;13(1):92. https:\/\/doi.org\/10.1007\/s40820-021-00622-6.","journal-title":"Nano-micro Lett"},{"issue":"3","key":"4973_CR42","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.biomaterials.2012.09.062","volume":"34","author":"Z Huang","year":"2013","unstructured":"Huang Z, Yang Y, Jiang Y, Shao J, Sun X, Chen J, Dong L, Zhang J. Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers. Biomaterials. 2013;34(3):746\u201355. https:\/\/doi.org\/10.1016\/j.biomaterials.2012.09.062.","journal-title":"Biomaterials"},{"issue":"8","key":"4973_CR43","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3390\/ph18081086","volume":"18","author":"MM Fallatah","year":"2025","unstructured":"Fallatah MM, Alradwan I, Alfayez N, Aodah AH, Alkhrayef M, Majrashi M, Jamous YF. Nanoparticles for Cancer Immunotherapy: Innovations and Challenges. Pharmaceuticals (Basel Switzerland). 2025;18(8):1086. https:\/\/doi.org\/10.3390\/ph18081086.","journal-title":"Pharmaceuticals (Basel Switzerland)"},{"issue":"11","key":"4973_CR44","doi-asserted-by":"publisher","first-page":"7769","DOI":"10.1021\/acsnano.3c12387","volume":"18","author":"SL Li","year":"2024","unstructured":"Li SL, Hou HY, Chu X, Zhu YY, Zhang YJ, Duan MD, Liu J, Liu Y. Nanomaterials-Involved Tumor-Associated Macrophages\u2019 Reprogramming for Antitumor Therapy. ACS Nano. 2024;18(11):7769\u201395. https:\/\/doi.org\/10.1021\/acsnano.3c12387.","journal-title":"ACS Nano"},{"issue":"1","key":"4973_CR45","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41420-024-02092-2","volume":"10","author":"X Han","year":"2024","unstructured":"Han X, Zhu Y, Ke J, Zhai Y, Huang M, Zhang X, He H, Zhang X, Zhao X, Guo K, Li X, Han Z, Zhang Y. Progression of m6A in the tumor microenvironment: hypoxia, immune and metabolic reprogramming. Cell death discovery. 2024;10(1):331. https:\/\/doi.org\/10.1038\/s41420-024-02092-2.","journal-title":"Cell death discovery"},{"key":"4973_CR46","doi-asserted-by":"publisher","first-page":"114833","DOI":"10.1016\/j.biopha.2023.114833","volume":"163","author":"S Sisakhtnezhad","year":"2023","unstructured":"Sisakhtnezhad S, Rahimi M, Mohammadi S. Biomedical applications of MnO2 nanomaterials as nanozyme-based theranostics. Biomed pharmacotherapy = Biomedecine pharmacotherapie. 2023;163:114833. https:\/\/doi.org\/10.1016\/j.biopha.2023.114833.","journal-title":"Biomed pharmacotherapy = Biomedecine pharmacotherapie"},{"key":"4973_CR47","doi-asserted-by":"publisher","first-page":"1764525","DOI":"10.3389\/fimmu.2025.1764525","volume":"16","author":"W Fang","year":"2026","unstructured":"Fang W, Qiu E, Liu R, Wang S, Wang T, Wang Y. Exo-nanomaterials in cancer immunotherapy: reprogramming the tumor immune microenvironment. Front Immunol. 2026;16:1764525. https:\/\/doi.org\/10.3389\/fimmu.2025.1764525.","journal-title":"Front Immunol"},{"issue":"1","key":"4973_CR48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.apsb.2025.10.019","volume":"16","author":"Z Sun","year":"2026","unstructured":"Sun Z, Ge J, Fu H, Chen Z, Zhao C, Li X, Sun Y, Gao Z, Li Y, Li Y. Immunocyte reprogramming empowers live-cell drug delivery: Mechanistic insights, delivery strategies, and clinical perspectives. Acta Pharm Sinica B. 2026;16(1):169\u201397. https:\/\/doi.org\/10.1016\/j.apsb.2025.10.019.","journal-title":"Acta Pharm Sinica B"},{"issue":"1","key":"4973_CR49","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1080\/10717544.2021.1909175","volume":"28","author":"S Song","year":"2021","unstructured":"Song S, Xia H, Guo M, Wang S, Zhang S, Ma P, Jin Y. Role of macrophage in nanomedicine-based disease treatment. Drug Delivery. 2021;28(1):752\u201366. https:\/\/doi.org\/10.1080\/10717544.2021.1909175.","journal-title":"Drug Delivery"},{"issue":"1","key":"4973_CR50","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1038\/s41467-025-60927-7","volume":"16","author":"F Chen","year":"2025","unstructured":"Chen F, Zhang H, Li S, Ren S, Huang L, Cai Z, Yin L, Zheng M, Liu X, Xu Z, Yu H. Engineering STING Nanoadjuvants for spatiotemporally-tailored innate immunity stimulation and cancer vaccination therapy. Nat Commun. 2025;16(1):5773. https:\/\/doi.org\/10.1038\/s41467-025-60927-7.","journal-title":"Nat Commun"},{"key":"4973_CR51","doi-asserted-by":"publisher","first-page":"113846","DOI":"10.1016\/j.jconrel.2025.113846","volume":"383","author":"S Liang","year":"2025","unstructured":"Liang S, Ma H, Liu Y, Hai L, Tian Y, Sun Y, Wang Z. Nano-immunomodulator amplifies STING activation in tumor-associated macrophages for cancer immunotherapy. J controlled release: official J Controlled Release Soc. 2025;383:113846. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113846.","journal-title":"J controlled release: official J Controlled Release Soc"},{"issue":"1","key":"4973_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1515\/jtim-2025-0004","volume":"13","author":"Z Guo","year":"2025","unstructured":"Guo Z, Liu Y, Chen D, Sun Y, Li D, Meng Y, Zhou Q, Zeng F, Deng G, Chen X. Targeting regulated cell death: Apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis in anticancer immunity. J translational Intern Med. 2025;13(1):10\u201332. https:\/\/doi.org\/10.1515\/jtim-2025-0004.","journal-title":"J translational Intern Med"},{"issue":"1","key":"4973_CR53","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/s12951-022-01746-6","volume":"20","author":"Y Wu","year":"2022","unstructured":"Wu Y, Wan S, Yang S, Hu H, Zhang C, Lai J, Zhou J, Chen W, Tang X, Luo J, Zhou X, Yu L, Wang L, Wu A, Fan Q, Wu J. Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment. J Nanobiotechnol. 2022;20(1):542. https:\/\/doi.org\/10.1186\/s12951-022-01746-6.","journal-title":"J Nanobiotechnol"},{"issue":"8","key":"4973_CR54","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/membranes12080738","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhang X, Li H, Liu J, Wei W, Gao J. Membrane-Coated Biomimetic Nanoparticles: A State-of-the-Art Multifunctional Weapon for Tumor Immunotherapy. Membranes. 2022;12(8):738. https:\/\/doi.org\/10.3390\/membranes12080738.","journal-title":"Membranes"},{"key":"4973_CR55","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3389\/fbioe.2020.00627","volume":"8","author":"M Sushnitha","year":"2020","unstructured":"Sushnitha M, Evangelopoulos M, Tasciotti E, Taraballi F. Cell Membrane-Based Biomimetic Nanoparticles and the Immune System: Immunomodulatory Interactions to Therapeutic Applications. Front Bioeng Biotechnol. 2020;8:627. https:\/\/doi.org\/10.3389\/fbioe.2020.00627.","journal-title":"Front Bioeng Biotechnol"},{"key":"4973_CR56","doi-asserted-by":"publisher","first-page":"13615","DOI":"10.2147\/IJN.S491573","volume":"19","author":"R Li","year":"2024","unstructured":"Li R, Huang J, Wei Y, Wang Y, Lu C, Liu J, Ma X. Nanotherapeutics for Macrophage Network Modulation in Tumor Microenvironments: Targets and Tools. Int J Nanomed. 2024;19:13615\u201351. https:\/\/doi.org\/10.2147\/IJN.S491573.","journal-title":"Int J Nanomed"},{"issue":"1","key":"4973_CR57","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12943-025-02443-2","volume":"24","author":"C Yang","year":"2025","unstructured":"Yang C, Li S, Wang L. Engineered iron oxide nanoplatforms: reprogramming immunosuppressive niches for precision cancer theranostics. Mol Cancer. 2025;24(1):225. https:\/\/doi.org\/10.1186\/s12943-025-02443-2.","journal-title":"Mol Cancer"},{"issue":"12","key":"4973_CR58","doi-asserted-by":"publisher","first-page":"8996","DOI":"10.1021\/acsnano.3c12745","volume":"18","author":"Q Cheng","year":"2024","unstructured":"Cheng Q, Shi X, Chen Y, Li Q, Wang J, Li H, Wang L, Wang Z. Tumor Microenvironment-Activatable Nanosystem Capable of Overcoming Multiple Therapeutic Obstacles for Augmenting Immuno\/Metal-Ion Therapy. ACS Nano. 2024;18(12):8996\u20139010. https:\/\/doi.org\/10.1021\/acsnano.3c12745.","journal-title":"ACS Nano"},{"key":"4973_CR59","doi-asserted-by":"publisher","first-page":"102385","DOI":"10.1016\/j.mtbio.2025.102385","volume":"35","author":"X Deng","year":"2025","unstructured":"Deng X, Liu X, Zhao L. Multifunctional nanoplatforms for tumor microenvironment remodeling: Toward precision and intelligent cancer therapy. Mater today Bio. 2025;35:102385. https:\/\/doi.org\/10.1016\/j.mtbio.2025.102385.","journal-title":"Mater today Bio"},{"issue":"1","key":"4973_CR60","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/pro6.1225","volume":"8","author":"K Meng","year":"2024","unstructured":"Meng K, Lu H. Clinical application of high-LET radiotherapy combined with immunotherapy in malignant tumors. Precision radiation Oncol. 2024;8(1):42\u20136. https:\/\/doi.org\/10.1002\/pro6.1225.","journal-title":"Precision radiation Oncol"},{"issue":"4","key":"4973_CR61","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/pro6.70043","volume":"9","author":"J Han","year":"2025","unstructured":"Han J, Hua Y, Wu X, Tang X, Liu C. Chemoradioimmunotherapy versus chemoimmunotherapy or chemoradiotherapy in extensive-stage small-cell lung cancer: A retrospective analysis of survival outcomes. Precision radiation Oncol. 2025;9(4):295\u2013303. https:\/\/doi.org\/10.1002\/pro6.70043.","journal-title":"Precision radiation Oncol"},{"key":"4973_CR62","doi-asserted-by":"publisher","unstructured":"Wang, W., He, Y., Yuan, X., Weng, L., Bai, J., Liu, X., Han, L., Xu, J., Wang, S.,Lu, S., Bai, J., Quan, H., Liu, Q., Li, X., Xiao, Y., Wang, Y., Zhang, Q., Zhou, N.,Hou, Y., Li, H., \u2026 CLEVER Consortium (2025). Protocol for Chinese lung cancer evolution and microenvironment tracking under therapy study. Journal of translational internal medicine, 13(6), 599\u2013609. https:\/\/doi.org\/10.1515\/jtim-2025-0047.","DOI":"10.1515\/jtim-2025-0047."},{"issue":"1","key":"4973_CR63","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/pro6.70002","volume":"9","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yang X, Xiao H, Guan F, Aneja S. Hypofractionated radiotherapy (RT) combined with dihydroartemisinin (DHA): No synergistic effect observed in a preliminary animal study. Precision radiation Oncol. 2025;9(1):54\u201360. https:\/\/doi.org\/10.1002\/pro6.70002.","journal-title":"Precision radiation Oncol"}],"container-title":["Discover Nano"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-026-04973-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11671-026-04973-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-026-04973-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:02:57Z","timestamp":1791849777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11671-026-04973-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4973"],"URL":"https:\/\/doi.org\/10.1186\/s11671-026-04973-0","relation":{},"ISSN":["2731-9229"],"issn-type":[{"value":"2731-9229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"15 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NA.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"504"}}